This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed ADCETRIS click here.

ADCETRIS significantly improved ORR4 vs physician’s choice1

  • ADCETRIS significantly improved ORR4 vs. physician’s choice per IRF (56.3% vs. 12.5%; P<0.0001)*
  • ORR4 benefit with ADCETRIS was maintained across key subgroups, including disease type (pcALCL/MF) and physician’s choice (methotrexate/bexarotene)

Study details ORR4 definition

*ORR4 was 15.8% with bexarotene and 7.7% with methotrexate.1

ORR4 determined by IRF (ITT population)1
ORR4 determined by IRF (ITT population)

Median duration of treatment for ADCETRIS was 12 cycles (~9 months)1

Adapted from Prince HM, et al. 2017

ADCETRIS delivered improved ORR and complete response rates vs. physician’s choice1,3*

Objective response rates per IRF (ITT population)1,3†
Objective response rates per IRF

Adapted from Prince HM, et al. 2017.

  • With ADCETRIS, 15.6% of patients achieved CR vs 1.6% with physician's choice (adjusted P=0.0046)4

*CTCL subtypes included in the ALCANZA trial were MF and pcALCL.1

ORR was 26.3% (0% CR; 26.3% PR) with bexarotene and 11.5% (3.8% CR; 7.7% PR) with methotrexate.3

ADCETRIS significantly extended progression-free survival vs. physician’s choice1

  • ADCETRIS extended median PFS by 13.2 months vs. physician's choice (16.7 months vs 3.5 months; HR=0.27; P<0.0001)1
Progression-free survival (ITT population)
Objective response rates per IRF

Adapted from Prince HM, et al. 2017.

ADCETRIS improved patient-reported symptoms, including skin symptoms vs. physician's choice in CTCL1

  • Symptom burden, measured by the symptom domain of health-related quality of life (HRQL) measure, Skindex-29, was a key secondary endpoint in the ALCANZA trial1
  • Skindex-29 measures the impact of skin disease across three domains: symptoms, emotions and functioning6
  • Mean of the maximum reduction of patient-reported burden of symptoms was significantly greater for ADCETRIS versus physician’s choice:
    • -27.96 for ADCETRIS
    • -8.62 for physician’s choice (adjusted p <0.0001)
  • No substantial difference in Skindex-29 emotional or functioning domains was seen over time1
Mean change in Skindex-29 symptom domain score from baseline1
Mean maximum reduction in patient-reported symptoms

Adapted from Kim YH, et al. 2016.

ADCETRIS demonstrated a generally manageable tolerability profile in patients with CTCL1

  • AEs were consistent with the established safety profile of ADCETRIS in the monotherapy setting1,4
  • Peripheral neuropathy was the most common treatment-emergent AE associated with ADCETRIS and was observed to be reversible and manageable in most cases1,4
Most common (≥15%) any grade treatment-emergent AEs in ALCANZA1
Most common (≥15%) any grade treatment-emergent AEs in ALCANZA

Symptoms of peripheral neuropathy (PN) in ALCANZA were generally manageable and reversible1,4,7

  • Peripheral neuropathy (PN) is typically an effect of cumulative exposure to ADCETRIS, making it predictable4
Peripheral neuropathy (PN) is typically an effect of cumulative exposure to ADCETRIS, making it predictable
  • In the ALCANZA trial, PN was observed to be manageable and reversible in most cases7
    • 86% of patients with PN (n=38/44) had resolution or improvement of symptoms at the last follow-up (median follow-up: 33.9 months)7
    • Median time to resolution or improvement of PN was 30.0 weeks and 13.0 weeks respectively7
    • ADCETRIS patients who discontinued due to PN received a median of 11 cycles7 (median for all ADCETRIS patients: 12 cycles)1
  • Majority of PN cases were low grade (Grade 1, 26%; Grade 2, 32%), with 9% of Grade 3 PN and no cases of Grade 4 PN7

Q3W: every 3 weeks.
*using a Kaplan-Meier estimate including all patients in the ALCANZA safety population

Not funded. Available via IPTR/private funding
Northern Ireland

Treatment of CD30+ CTCL patient with brentuximab vedotin

Dr Sridhar Chaganti

Consultant Haematologist, Queen Elizabeth Hospital, Birmingham

Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at

Adverse events should also be reported to Takeda on 01628 537900 or e-mail